miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis

Binhua Wu1, Ligang Zhang, Yunfei Yu1

  • 1Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Biology, Jinan University, Guangzhou, 510632, China.

Insights

MicroRNA 6086 (miR-6086) suppresses ovarian cancer growth and angiogenesis by targeting the OC2/VEGFA/EGFL6 pathway. This finding offers potential therapeutic targets for ovarian cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression involved in cellular processes.
  • The precise mechanisms by which miRNAs, transcription factors, and effector proteins control ovarian cancer cell fate, particularly tumor angiogenesis, require further elucidation.

Purpose of the Study:

  • To investigate the role of miR-6086 in ovarian cancer.
  • To identify the targets and regulatory pathways of miR-6086 involved in tumor angiogenesis.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC) for expression analysis.
  • Luciferase assays to confirm direct miRNA-target interactions.
  • Western blotting to assess protein expression and pathway activation.
  • In vitro assays for cell proliferation, migration, invasion, and vascular formation.
  • In vivo studies using ovarian cancer xenografts in animal models.

Main Results:

  • miR-6086 expression is significantly downregulated in ovarian cancer cell lines and tissues.
  • OC2 and EGFL6 were identified as direct targets of miR-6086.
  • An inverse correlation was observed between miR-6086 and the OC2/VEGFA/EGFL6 axis.
  • miR-6086, siOC2, and siEGFL6 inhibited ovarian cancer growth and angiogenesis in vivo.
  • Tumor cell proliferation, migration, invasion, and vascular formation were suppressed in vitro via the AKT/MAPK pathways.

Conclusions:

  • miR-6086 suppresses ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis.
  • This regulatory network presents a potential therapeutic strategy for ovarian cancer.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K